Novo Nordisk is convicted of violating a competitor

Novo Nordisk is convicted of violating a competitor

The two companies are direct competitors in the diabetes treatment market.

But in 2019, Novo Nordisk issued a press release comparing Novo Nordisk’s drug Tresiba with Sanofi’s Toujeo, which was misleading, the court states.

The judges emphasize that Novo Nordisk also crossed the line in 2017 by issuing an illegal press release, and that Sanofi was also violated at the time.

The Maritime and Commercial Court cannot see mitigating circumstances. As a large global pharmaceutical company, the Danish company must “be assumed to have in-depth knowledge of rules and professional standards in relation to communication of study results”, it is stated in the premises.

Source: The Nordic Page




Related Posts:

Ads Block Detector Powered by

Ads Blocker Detected!!!

Hi there! We have noticed that you are using an ad blocker. When you use an ad blocker, we will detect it and display this message. We understand that you want to reduce the annoyance of ads, but we also want you to know that ads are our main source of revenue to keep our website running. If you are willing to disable your ad blocker or whitelist our website, we can continue to provide high-quality content and services. In addition, you can enjoy a better browsing experience as the ads will display more relevant content based on your interests. Thank you for your understanding and support!